ClinicalTrials.gg
TerminatedNCT02284906Updated Jul 2, 2019Results posted

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

A Phase 3 interventional study of Pioglitazone and Placebo in Mild Cognitive Impairment Due to Alzheimer's Disease, sponsored by Takeda. Terminated at 43 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of efficacy of the drug; no safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,039th of 1,609
40 · median 73
Started
2015
with 71 others
Phase 3
188 of 1,940
19 open now
Registered
667th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,039th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 188 in phase 3, and was the 667th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

Read the detailed description

The drug being tested in this study is called pioglitazone. This study is designed to further evaluate the safety and effectiveness of pioglitazone on cognitive function in participants who have completed the AD-4833/TOMM40_301. This study will look at the effectiveness of pioglitazone on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study with a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

The study enrolled 40 participants, but is dependent on how many decide to continue treatment in an extension phase after completing the main (301) study. Participants will continue to receive the same study medication they received during the pivotal AD-4833/TOMM40_301 study, either:

  • Pioglitazone 0.8 mg tablets or
  • Placebo (this is a tablet that looks like the study drug but has no active ingredient).

All participants will be asked to take one tablet at the same time each day throughout the study.

This multi-centre trial, like its precedent pivotal trial, will be conducted worldwide. The overall time to participate in this study is minimum 2 years and a maximum of 7 years depending on when participants roll over from the 301 study. Participants will make approximately 2 visits per year to the clinic, and will be contacted by telephone 3 months after each treatment visit for a follow-up assessment, and 2 weeks after the final visit.

03

Conditions studied

  • Mild Cognitive Impairment Due to Alzheimer's Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) without ongoing serious adverse events (SAEs) from AD-4833/TOMM40_301.
  2. Is male or female and is at least 65 years of age at the time of the Baseline Visit.
  3. In the opinion of the investigator, is capable of understanding and complying with the protocol requirements.
  4. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  5. Must be living independently or in nonmedical residential care.
  6. Has a project partner able to separately consent on his/her own behalf and take part in the study (with the intent to do so as long as the participant is enrolled), providing information on the cognitive, functional, and behavioral status of the participant and assisting with observation of adverse events (AEs) and monitoring of study medication, if needed. Project partners participating in the pivotal AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this capacity.

Exclusion criteria

Exclusion Criteria:

  1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of AD dementia.
  2. Has a current diagnosis of significant psychiatric illness, per , 4th Edition (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the participant has a current diagnosis or history of schizophrenia or bipolar disorder.
  3. Has a glycosylated () >8% at the extension study Baseline Visit or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist.
  4. Has a unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass surgery), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
  5. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, pivotal, child, sibling) or may consent under duress.
  6. Is required to take excluded medications.
  7. Has a history of or allergies to pioglitazone or related compounds.
  8. Had any of the following values at the extension study Baseline Visit:

    1. A serum total value >15 x (ULN).
    2. A serum (ALT) or aspartate aminotransferase (AST) value >2 x ULN.
    3. Unexplained microscopic/macroscopic hematuria on 2 repeat examinations within 2 weeks.
  9. Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the participant from adequately participating in the study or continue for the anticipated duration of the study.
  10. Has received any compound, with the exception of treatment during the AD-4833/TOMM40_301 study, within 30 days prior to Baseline or 5 half-lives prior to Baseline or is currently participating in another study that entails the administration of an investigational or marketed drug, supplement, or intervention including, but not limited to diet, exercise, lifestyle, or invasive procedure.
  11. Has any cancer that has been in remission for less than 2 years from the extension study Baseline Visit. Participants with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Participants with current diagnosis of bladder cancer are not eligible irrespective of the remission status.
  12. Has a current diagnosis of macular edema, degeneration or any maculopathy.
  13. Has a history or current diagnosis of congestive heart failure (CHF), class III-IV.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Pioglitazone 0.8 mg

    Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.

    Drug: Pioglitazone

  • Placebo comparator
    Placebo

    Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.

    Drug: Placebo

Interventions

  • Pioglitazone tablets

    Also known as: AD-4833

  • DrugPlacebo

    Pioglitazone placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24

    Composite scores were derived from the test battery. Each test in the battery falls into 1 of the following cognitive domains: Episodic Memory (California Verbal Learning Test - 2nd Edition \[CVLT-II\], Brief Visuospatial Memory Test - Revised \[BVMT-R\]), Executive Function (Trail Making Part B, Digit Span Backwards), Language (Animals, Lexical/Phonemic Fluency), Attention (Digit Span Forward, Trail Making Part A), and Visuospatial (Clock Drawing, BVMT-Copy). Only the domains of episodic memory, executive function, language, and attention were used for the calculation of composite score (i.e., Clock Drawing, BVMT-Copy, and the Multilingual Naming Test (MINT), which do not allow generation of standard z scores, were only used for diagnostic purposes and were excluded from the calculation of the composite score). To form the composite, z-scores were calculated for each test, each z-score for the domain were averaged, and then all relevant domains were averaged to form the composite.

    Time frame: Baseline and Month 24

Secondary outcomes

  1. Time to Diagnosis of Alzheimer's Disease (AD) Dementia

    Time frame: Day 1 and every 6 months (up to maximum of 36 months)

07

Results

Posted Jul 2, 2019

Participant flow

Participants took part in the study at 3 investigative sites in Australia, United Kingdom and United States from 12 Feb 2015 to 08 May 2018.

Participant flow — Overall Study
MilestoneLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
Started31819
Completed000
Not completed31819
Withdrew: Pretreatment event/adverse event010
Withdrew: Major protocol deviation010
Withdrew: Voluntary withdrawal245
Withdrew: Study termination01114
Withdrew: Reason not specified110

Outcome measures

PrimaryChange From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24

Composite scores were derived from the test battery. Each test in the battery falls into 1 of the following cognitive domains: Episodic Memory (California Verbal Learning Test - 2nd Edition \[CVLT-II\], Brief Visuospatial Memory Test - Revised \[BVMT-R\]), Executive Function (Trail Making Part B, Digit Span Backwards), Language (Animals, Lexical/Phonemic Fluency), Attention (Digit Span Forward, Trail Making Part A), and Visuospatial (Clock Drawing, BVMT-Copy). Only the domains of episodic memory, executive function, language, and attention were used for the calculation of composite score (i.e., Clock Drawing, BVMT-Copy, and the Multilingual Naming Test (MINT), which do not allow generation of standard z scores, were only used for diagnostic purposes and were excluded from the calculation of the composite score). To form the composite, z-scores were calculated for each test, each z-score for the domain were averaged, and then all relevant domains were averaged to form the composite.

Time frame:
Baseline and Month 24

No measurements were reported for this outcome.

SecondaryTime to Diagnosis of Alzheimer's Disease (AD) Dementia
Time frame:
Day 1 and every 6 months (up to maximum of 36 months)

No measurements were reported for this outcome.

Adverse events

Collected over Up to 30 days after receiving the last dose of study drug (approximately up to 1113 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Risk Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
High Risk Placebo0/18 (0%)4/18 (22.2%)10/18 (55.6%)
High Risk Pioglitazone0/19 (0%)3/19 (15.8%)12/19 (63.2%)
Most frequent serious events
Most frequent serious events
EventLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
Cardiac failure congestiveCardiac disorders0/31/180/19
Myocardial infarctionCardiac disorders0/31/180/19
Non-cardiac chest painGeneral disorders0/31/180/19
LacerationInjury, poisoning and procedural complications0/31/180/19
Back painMusculoskeletal and connective tissue disorders0/31/180/19
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/180/19
Retinal artery occlusionEye disorders0/30/181/19
Femur fractureInjury, poisoning and procedural complications0/30/181/19
Hip fractureInjury, poisoning and procedural complications0/30/181/19
Benign prostatic hyperplasiaReproductive system and breast disorders0/30/181/19
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
DiarrhoeaGastrointestinal disorders1/30/180/19
Dementia Alzheimer's typeNervous system disorders1/30/180/19
Upper respiratory tract infectionInfections and infestations0/32/184/19
Urinary tract infectionInfections and infestations0/32/181/19
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/32/180/19
CataractEye disorders0/30/182/19
FallInjury, poisoning and procedural complications0/31/182/19
ArthralgiaMusculoskeletal and connective tissue disorders0/30/182/19
Pancreatic cystGastrointestinal disorders0/31/180/19
ContusionInjury, poisoning and procedural complications0/31/180/19

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of blinded study medication.

Age, Continuous
Age, Continuous(years)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Mean74.7 ± 4.7378.9 ± 3.9878.1 ± 4.4278.2 ± 4.27
Sex: Female, Male
Sex: Female, Male(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Female151016
Male213924
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Hispanic or Latino1113
Not Hispanic or Latino2171837
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Black or African American0011
White3181839
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Non-Hispanic/Latino Caucasian2171736
Hispanic/Latino and/or non-Caucasian1124
Region of Enrollment
Region of Enrollment(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
United States2111528
United Kingdom1225
Australia0527
Height
Height(cm)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Mean169.7 ± 4.16168.7 ± 10.85166.8 ± 11.73167.9 ± 10.81
Weight
Weight(kg)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Mean78.20 ± 6.05376.00 ± 13.71972.11 ± 15.68574.32 ± 14.224

11 further baseline measures are reported on the registry.

08

Study locations

43 sites
  • Phoenix, Arizona 85006, United States
  • Sun City, Arizona 85351, United States
  • San Diego, California 92103, United States
  • Delray Beach, Florida 33445, United States
  • Fort Myers, Florida 33912, United States
  • Lake Worth, Florida 33449, United States
  • Melbourne, Florida 32940, United States
  • Merritt Island, Florida 32952, United States
  • Port Orange, Florida 32127, United States
  • Saint Petersburg, Florida 33709, United States
  • Weston, Florida 33331, United States
  • Atlanta, Georgia 30329, United States
  • Decatur, Georgia 30033, United States
  • Chicago, Illinois 60640, United States
  • Elk Grove Village, Illinois 60007, United States
  • Elk Grove, Illinois 60007, United States
  • Iowa City, Iowa 52242, United States
  • Saint Louis, Missouri 63141, United States
  • Las Vegas, Nevada 89106, United States
  • Marlton, New Jersey 08053, United States
  • New York, New York 10019, United States
  • Concord, North Carolina 28025, United States
  • Durham, North Carolina 27705, United States
  • Akron, Ohio 44320, United States
  • Charleston, South Carolina 29401, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 84107, United States
  • Middleton, Wisconsin 53562, United States
  • North Ryde, New South Wales 2113, Australia
  • Southport, Queensland 4215, Australia
  • Heidelberg West, Victoria 3081, Australia
  • Nedlands, Western Australia 6009, Australia
  • Basel, CH-4012, Switzerland
  • Bristol, Avon BS16 1LE, United Kingdom
  • Exeter, Devon EX2 5DW, United Kingdom
  • Plymouth, Devon PL6 8DH, United Kingdom
  • Hammersmith, Greater London W6 8RF, United Kingdom
  • London, Greater London EC1M 6BQ, United Kingdom
  • Manchester, Greater Manchester M13 9NQ, United Kingdom
  • Blackpool, Lancashire FY2 0JH, United Kingdom
  • Isleworth, Middlesex TW7 6FY, United Kingdom
  • Glasgow, Strathclyde G20 0XA, United Kingdom
  • Perth, Tayside Region PH2 7BH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Jan 2018, 35 months.

Results were first posted in Jul 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2014
First posted
Nov 6, 2014
StartActual
Feb 12, 2015
Primary completionActual
Jan 31, 2018
CompletionActual
May 8, 2018
Results first posted
Jul 2, 2019
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02284906
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Feb 12, 2015
Primary completion
Jan 31, 2018
Completion
May 8, 2018
Results posted
Jul 2, 2019
Last update
Jul 2, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion